Deferred Tax Assets, Net of Valuation Allowance of ARS Pharmaceuticals, Inc. from 31 Dec 2020 to 31 Dec 2025

Taxonomy & unit: us-gaap: USD
Description: Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary: ARS Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Net of Valuation Allowance in USD history and change rate from 31 Dec 2020 to 31 Dec 2025.
ARS Pharmaceuticals, Inc. Deferred Tax Assets, Net of Valuation Allowance for the quarter ending 31 Dec 2025 was $73,800,000, a 99% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Net of Valuation Allowance, Quarterly (USD)

Deferred Tax Assets, Net of Valuation Allowance, YoY Quarterly Change (%)

ARS Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Net of Valuation Allowance (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2025	$73,800,000	+$36,799,000	+99%	31 Dec 2025	10-K	09 Mar 2026	2025	FY
Q4 2024	$37,001,000	+$7,845,000	+27%	31 Dec 2024	10-K	09 Mar 2026	2025	FY
Q4 2023	$29,156,000	+$11,150,000	+62%	31 Dec 2023	10-K	20 Mar 2025	2024	FY
Q4 2022	$18,006,000	+$8,727,000	+94%	31 Dec 2022	10-K	21 Mar 2024	2023	FY
Q4 2021	$9,279,000	-$12,068,000	-57%	31 Dec 2021	10-K	23 Mar 2023	2022	FY
Q4 2020	$21,347,000			31 Dec 2020	10-K	31 Mar 2022	2021	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.